Brief: Poseida Therapeutics Receives Notice From Takeda Pharmaceuticals To Terminate Certain Collaboration & License Agreement

Poseida Therapeutics

01/06/2023 23:01

June 1 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS - ON MAY 31, RECEIVED NOTICE FROM
TAKEDA
PHARMACEUTICALS TO TERMINATE CERTAIN COLLABORATION & LICENSE
AGREEMENT
    * POSEIDA THERAPEUTICS INC -  TERMINATION OF THE
COLLABORATION
AGREEMENT WILL BE EFFECTIVE JULY 30, 2023
    * POSEIDA THERAPEUTICS INC - UPON TERMINATION OF
COLLABORATION
AGREEMENT, CO MAY SEEK NEW STRATEGIC COLLABORATIONS IN GENE
THERAPY
    * POSEIDA THERAPEUTICS INC -  UNTIL TERMINATION DATE,
PARTIES WILL
CONTINUE TO PERFORM THEIR RESPECTIVE OBLIGATIONS UNDER
COLLABORATION AGREEMENT
    * POSEIDA THERAPEUTICS INC - UPON THE TERMINATION DATE, CO'S
EXCLUSIVITY OBLIGATIONS UNDER COLLABORATION AGREEMENT WILL
TERMINATE
    * POSEIDA THERAPEUTICS - LICENSES GRANTED TO TAKEDA BY CO,
LICENSES GRANTED TO CO BY TAKEDA TO PERFORM RESEARCH UNDER
AGREEMENT, WILL EACH TERMINATE

Source text for Eikon:  ID: 
Further company coverage:  PSTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))